If you're comparing Wegovy vs Mounjaro in the UK, a prominent headline figure stands out: in a head-to-head study reported by the British Heart Foundation, people with obesity lost 20.2% of body weight on tirzepatide and 13.7% on semaglutide. That 6.5 percentage point gap matters, but it isn't the whole decision.
In practice, these are both prescription-only treatments that need medical assessment, ongoing review, and realistic expectations. They aren't over-the-counter appetite suppressants, and they aren't interchangeable because both are weekly injections. For many UK patients, the better question isn't only “which causes more weight loss?” but “which option best matches my health goals, risk profile, and route of access through a regulated service?”
Both medicines sit within the broader group of therapies that affect appetite regulation and metabolic control. They are usually considered alongside changes to diet, physical activity, sleep, and long-term weight maintenance planning. Some people also want non-medicinal support first, so it can help to explore plant-based weight loss solutions as part of a broader, evidence-aware approach to lifestyle change.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any treatment.
Table of Contents
- Introduction Understanding Your Weight Loss Options
- How Wegovy and Mounjaro Work
- Clinical Efficacy A Head to Head Comparison
- Side Effects and Safety Profiles
- UK Availability Cost and Access
- Making an Informed Decision for Your Health
- Frequently Asked Questions
Introduction Understanding Your Weight Loss Options
Wegovy and Mounjaro are two of the main prescribed medications now discussed in UK weight management. Both are once-weekly injections used under clinical supervision, but they are not the same medicine and they don't have identical strengths, licensing history, or practical use.
For patients, that distinction matters. Some arrive focused on the strongest average weight-loss effect. Others are equally concerned about tolerability, longer-term health outcomes, previous diabetes treatment, or whether an online pharmacy or local service is operating to the right standard. In UK practice, those points can change the conversation quickly.
A simple comparison also misses the regulatory context. Wegovy is identified in UK-facing guidance as semaglutide, and Mounjaro as tirzepatide. Wegovy is positioned as a weight-management medicine, while Mounjaro was originally developed and approved for type 2 diabetes, although both are weekly injections, as outlined in this UK-facing overview from WeightWatchers.
The safest starting point is a proper prescribing assessment, not a social media comparison or a price list.
If you're using a UK-registered pharmacy or telehealth provider, the process should be built around eligibility, contraindications, previous medical history, and follow-up. Access to a medication should never be automatic just because a patient asks for it. That matters even more with GLP-1 based treatments, where side effects, dose escalation, and treatment goals all need active review.
How Wegovy and Mounjaro Work
The science is easier to understand than many people expect. Both medicines act on hormone pathways involved in appetite, fullness, and blood sugar regulation. That is why people often report reduced hunger, earlier fullness, and better control over eating patterns when treatment is working as intended.
The key difference in mechanism
The practical difference is this. Wegovy contains semaglutide, which is a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which is a dual GIP/GLP-1 receptor agonist. UK-facing clinical sources consistently treat that mechanism difference as central to the comparison, because it helps explain why the two medicines can perform differently and why they are not directly interchangeable without clinical guidance, as summarised by Second Nature.
In plain English, Wegovy works on one key signalling pathway. Mounjaro works on two related pathways. That doesn't mean one is automatically right for every person, but it does help explain why prescribers discuss Mounjaro as potentially having a stronger metabolic effect in some patients.
A helpful way to think about it is that both medicines turn down appetite signalling, but Mounjaro uses an additional hormonal lever. For some people that may improve effect. For others, the deciding factor is still tolerance, previous response, or the broader reason treatment is being prescribed.
If you want a patient-friendly explanation of tirzepatide specifically, this guide on how Mounjaro works for weight loss is a useful companion read.
Why titration matters
Neither medicine is started at its highest strength. Wegovy starts at 0.25 mg weekly and Mounjaro starts at 2.5 mg weekly, with doses increased gradually over time. UK-facing guidance also describes maximum doses of 7.2 mg for Wegovy and 15 mg for Mounjaro in the sources provided earlier.
That gradual increase is called titration. It exists for a reason. The aim isn't to rush to the top dose. The aim is to improve tolerability and find a dose that is both effective and manageable.
Practical rule: patients usually do better when the dose is advanced carefully and side effects are reviewed at each step, rather than treating escalation as a race.
Later in treatment, the gap in efficacy may narrow at higher maintenance doses. That nuance matters if someone is balancing weight-loss expectations against how well they tolerate dose increases.
For a visual summary, this short explainer can help:
Clinical Efficacy A Head to Head Comparison
In the direct comparison discussed earlier, tirzepatide produced greater average weight loss than semaglutide in adults with obesity without type 2 diabetes. That gives a useful benchmark, but trial averages are only one part of a safe prescribing decision in UK practice.
For patients, the practical question usually goes beyond which injection led to the larger average drop on the scales. The more useful question is whether the medicine is suitable, likely to be tolerated, and appropriate to continue under monitored follow-up through a regulated service. NICE criteria, existing health conditions, cardiovascular risk, and private cost all affect that discussion.
Comparison table
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug type | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Dosing frequency | Once weekly | Once weekly |
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Maximum dose described in UK-facing source | 7.2 mg | 15 mg |
| Head-to-head average weight loss | 13.7% in the study referenced earlier | 20.2% in the study referenced earlier |
Those figures matter, but they do not guarantee an individual result. In clinic, response varies for predictable reasons: dose escalation may pause, side effects may limit progress, adherence may be inconsistent, and some patients respond better to one drug than another.
A head-to-head trial is helpful because it reduces some of the guesswork that comes from comparing separate studies. Even so, routine UK care is different from a trial setting. Patients may face supply interruptions, holidays, intercurrent illness, difficulty progressing doses, or stopping and restarting treatment after side effects. Those practical factors often shape outcomes as much as the headline number.
How to interpret the trial result
A sensible reading of the evidence includes four points:
- Average results are not personal predictions: Some patients do well on semaglutide and stay on treatment consistently. Others may stop tirzepatide before reaching a dose that gives its full effect.
- Weight loss is a primary metric, but not the only clinically relevant outcome: Cardiovascular risk, blood pressure, glycaemic status, sleep apnoea, joint symptoms, and long-term treatment adherence also matter.
- Suitability can outweigh headline efficacy: A clinician still needs to check contraindications, current medicines, previous pancreatitis history, pregnancy plans, eating disorder history, and whether the patient can use the treatment safely.
- UK access changes the practical choice: Some patients are deciding within NICE eligibility rules, while others are comparing private prescribing costs and follow-up models through telehealth providers.
That last point is often underappreciated. Wegovy has established cardiovascular outcome data in people with obesity and established cardiovascular disease, which may be relevant in some prescribing discussions. Mounjaro may offer greater average weight reduction, but that does not automatically make it the better fit for every patient sitting in front of a clinician.
For a broader UK view of how these options compare in practice, including prescribing context and access, this guide to the best weight loss injections in the UK is a useful companion piece.
Side Effects and Safety Profiles
The main side effects of both medicines are usually gastrointestinal. In clinic, the complaints patients most often recognise are nausea, vomiting, diarrhoea, constipation, bloating, reduced appetite, and sometimes reflux-type symptoms. That pattern fits with how these medicines work. They alter appetite signalling and can slow digestion, especially during dose increases.
Most side effects are most noticeable at the start of treatment or when moving up a dose. That doesn't make them trivial, but it does mean they often need to be managed with pacing, review, and practical dietary changes rather than immediate discontinuation.
What patients commonly notice
A careful prescriber usually focuses on four points:
- Meal size matters: Smaller meals are often better tolerated than large portions.
- Fatty and rich foods can worsen symptoms: Patients frequently notice that heavier meals trigger more nausea or indigestion.
- Dose escalation needs patience: A slower rise may be safer and more sustainable than pushing ahead while side effects are unsettled.
- Hydration matters: Vomiting, loose stools, or low intake can leave people dehydrated quickly.
Some discomfort early on doesn't automatically mean a medicine is wrong for you. Persistent or severe symptoms do need review.
The practical mistake I see most often is assuming that more medicine, faster, will always produce better results. It often doesn't. If a patient can't eat properly, can't drink enough, or feels unwell for prolonged periods, adherence drops and the treatment plan becomes unstable.
When extra caution is needed
These medicines are not suitable for everyone. A proper assessment should explore previous pancreatitis, gallbladder problems, significant gastrointestinal disease, pregnancy considerations, and any personal or family history that may make GLP-1 based treatment inappropriate. Prescribers also need to review other medicines, because delayed gastric emptying can affect how some oral treatments are tolerated or absorbed.
Patients should seek urgent medical attention if they develop severe or persistent abdominal pain, repeated vomiting, or symptoms that raise concern for dehydration or pancreatitis. That is one reason prescriber oversight matters. A regulated service shouldn't issue repeat supplies without checking how the patient is coping.
For UK patients using a GPhC regulated provider, safety should include initial screening, clear written advice, access to follow-up, and a route for escalation if symptoms become difficult to manage.
UK Availability Cost and Access
In the UK, both Wegovy and Mounjaro are medicines that require a prescription. Access may happen through NHS pathways or through private care, but either route should involve a clinical decision, not a retail transaction. In reality, many patients researching Wegovy vs Mounjaro are looking at private treatment because NHS access can depend on local service pathways, eligibility criteria, and operational capacity.
How access usually works
Within a regulated telehealth service, the expected process is straightforward:
- Medical assessment comes first. You provide information about weight history, current health, medicines, and contraindications.
- A UK-registered prescriber reviews suitability. If the treatment isn't appropriate, it shouldn't be issued.
- The medicine is dispensed by a regulated pharmacy. A legitimate service should clearly state that it is a prescription-only treatment and that supply depends on assessment.
- Follow-up is built in. Dose progression, side effects, and treatment goals need review over time.
Patients should also expect identity checks, safeguarding around misuse, and questions about previous treatment history. If a service appears to offer automatic checkout with minimal clinical review, that's a warning sign.
If you're reading about semaglutide access in a private setting, this overview of Wegovy in the UK gives a useful educational summary.
What regulated prescribing should include
A safe service should make the governance visible.
- Registered professionals: Prescribing decisions should be made by appropriately qualified UK clinicians.
- Pharmacy regulation: Dispensing should come through a provider regulated by the GPhC.
- Clear boundaries: Information should distinguish education from medical advice and should never imply guaranteed approval.
- Ongoing review: Continued supply should depend on safety, response, and whether treatment remains clinically appropriate.
Cost is an important part of the decision, but it isn't the only practical issue. Price can vary between providers and may change with dose, stock position, and what support is included. For most patients, the more useful question is whether the treatment is clinically suitable and realistically sustainable, rather than whether the first month looks affordable.
Making an Informed Decision for Your Health
Many comparisons stop at body weight. That is too narrow for good prescribing. The more useful question is what health outcome matters most for the individual patient in front of you.
Weight loss is not the only outcome
Wegovy has an important point in its favour. According to GoodRx's comparison summary, Wegovy is approved for reducing the risk of serious cardiovascular problems in certain adults, while Mounjaro is primarily positioned there as a type 2 diabetes medicine without the same additional approval in that summary.
That doesn't erase the stronger average weight-loss result seen with tirzepatide. It does mean the “best” option may change depending on the clinical goal. A patient focused on maximum average weight reduction may lean one way. A patient with significant cardiometabolic concern may need a different discussion.
More weight loss doesn't automatically mean better overall health for every patient.
That nuance is often missing from online comparisons. In day-to-day practice, some patients need a medicine chosen for the broadest health rationale, emphasizing overall well-being beyond the biggest headline figure on weight loss.
For readers who want to hear a broader lifestyle and nutrition perspective alongside the medical discussion, this conversation on understanding GLP-1 with a nutrition expert adds helpful context.
Examples of how a clinician may think about suitability
A few simplified examples show how this can play out.
- Patient focused on maximum average weight loss: The head-to-head data may make tirzepatide attractive, provided there are no contraindications and the patient understands the need for titration and monitoring.
- Patient with broader cardiovascular concerns: Wegovy may deserve closer consideration because the decision isn't only about appetite suppression or scale change.
- Patient who struggled with side effects on one agent: The choice may turn less on theory and more on what the patient can tolerate and continue safely.
- Patient seeking care through a remote provider: The quality of the telehealth pathway matters. A proper service should assess, prescribe, monitor, and document clearly.
This broader decision-making model applies across other areas of regulated private care too. Patients often value integrated support from services that understand both health and confidence-related goals, whether that involves a UK-registered pharmacy for prescribed medication or an in person aesthetics clinic offering botox, dermal fillers, skin boosters and polynucleotides (salmon DNA) where medical suitability and informed consent also matter.
Frequently Asked Questions
Can you switch between Wegovy and Mounjaro
Sometimes, yes. But it should only happen under medical supervision. These medicines have different dose structures and different titration pathways, so a safe switch isn't as simple as finishing one pen and starting the other at an assumed equivalent strength.
A clinician would usually review why the switch is being considered, whether side effects were the main issue, and whether there are any gaps needed between treatments.
Do you need to stay on treatment long term
Weight management treatment is usually thought about over the longer term, not as a short course with a permanent effect after stopping. If treatment is discontinued, appetite and previous eating patterns may return. That is why follow-up planning matters just as much as the initial prescription.
For many patients, the right question isn't “How fast can I stop?” but “What is the maintenance plan if I respond well?”
What support should a regulated telehealth service provide
Look for a service that offers more than dispatch and delivery. A safe model should include:
- Clinical screening before prescribing
- Dose review during treatment
- Side effect support if problems develop
- Clear communication about red flags and when to seek urgent help
- Pharmacy dispensing through a provider regulated by the GPhC
If you're using an online pharmacy, the standard should feel clinical and documented, not transactional.
Is one definitely better than the other
Not in every situation. The best answer depends on what outcome matters most, whether the medicine is suitable for your medical history, how you tolerate treatment, and whether the prescribing pathway is safe and regulated.
A medicine can be highly effective in studies and still be the wrong option for a particular patient.
If you're considering clinically supervised treatment through a regulated UK service, XO provides access to healthcare information, telehealth support, and prescribing pathways through a UK-registered pharmacy model. XO also includes XO Clinic, an in-person service for medically led aesthetics and wellness care. Always make decisions about prescribed medication through a qualified clinician who can assess your individual medical history, goals, and safety needs.
Reviewed by: Medical content prepared in a clinician-led, UK healthcare style
Review date: June 2026
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any treatment.
0 comments